Breast Cancer Research and Treatment

, Volume 136, Issue 2, pp 331–345

Role of epidermal growth factor receptor in breast cancer

Authors

  • Hiroko Masuda
    • Department of Breast Medical Oncology, Unit 1354The University of Texas MD Anderson Cancer Center
  • Dongwei Zhang
    • Department of Breast Medical Oncology, Unit 1354The University of Texas MD Anderson Cancer Center
  • Chandra Bartholomeusz
    • Department of Breast Medical Oncology, Unit 1354The University of Texas MD Anderson Cancer Center
  • Hiroyoshi Doihara
    • Department of Breast and Endocrine SurgeryOkayama University Hospital
  • Gabriel N. Hortobagyi
    • Department of Breast Medical Oncology, Unit 1354The University of Texas MD Anderson Cancer Center
    • Department of Breast Medical Oncology, Unit 1354The University of Texas MD Anderson Cancer Center
    • Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Unit 1354The University of Texas MD Anderson Cancer Center
Review

DOI: 10.1007/s10549-012-2289-9

Cite this article as:
Masuda, H., Zhang, D., Bartholomeusz, C. et al. Breast Cancer Res Treat (2012) 136: 331. doi:10.1007/s10549-012-2289-9

Abstract

Decades of research in molecular oncology have brought about promising new therapies which are designed to target specific molecules which promote tumor growth and survival. The epidermal growth factor receptor (EGFR) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies. However, results so far have been disappointing. One of the reasons for these unexpected results is the lack of biomarkers for predicting which patients are most likely to respond to EGFR inhibitors. Recent studies have shown that EGFR and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion and that high EGFR expression is an independent predictor of poor prognosis in IBC. Further, recent studies have shown that targeting EGFR enhances the chemosensitivity of TNBC cells by rewiring apoptotic signaling networks in TNBC. These studies indicate that EGFR-targeted therapy might have a promising role in TNBC and IBC. Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy—e.g., as a chemosensitizer or to prevent metastases—to treat these aggressive diseases.

Keywords

EGFRBreast cancerTargeted therapyTriple-negative breast cancerInflammatory breast cancer

Copyright information

© Springer Science+Business Media New York 2012